A Phase II Study of HPPH Photodynamic Therapy for Treatment of High Grade Dysplasia, Carcinoma In-Situ or Early Intramucosal Adenocarcinoma in Barrett's Esophagus. Randomization to Two PDT Treatment Regimens of HPPH (2-1 [Hexyloxyethyl]-2devinylpyropheophorbide-a) and Light
OBJECTIVES:
- Determine response in patients with high-grade dysplasia, carcinoma in situ, or early
intramucosal adenocarcinoma of the esophagus and Barrett's esophagus treated with
photodynamic therapy using HPPH.
- Determine the safety, in terms of toxicity to surrounding normal tissue, of this
regimen in these patients.
- Determine the toxic effects of this regimen on surrounding normal tissue in these
patients.
- Determine the incidence of adenocarcinoma in these patients after this treatment.
- Determine the magnitude and duration of increased skin sun sensitivity in patients
treated with this regimen.
- Determine the minimal erythemal dose of this regimen in these patients.
OUTLINE: This is a randomized study. Patients are stratified according to presence of
intramucosal tumor (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the
lesion is exposed to laser light endoscopically.
- Arm II: Patients receive HPPH as in arm I, but at a higher dose, followed by laser
light exposure.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this
study within 3 years.
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy
3 years
No
Hector R. Nava, MD, FACS
Principal Investigator
Roswell Park Cancer Institute
United States: Food and Drug Administration
CDR0000441205
NCT00281736
February 2004
Name | Location |
---|---|
Roswell Park Cancer Institute | Buffalo, New York 14263 |